Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 12Gastrointestinal 4CNS 4Tumor-Agnostic 3Gynecologic 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma 1Leukemia 1Glioblastoma 1Ependymoma 1Disease 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
neratinib × CNS × 1 year × Clear all
NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting
109 enrolled
CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

University of Rochester

Phase 2 Recruiting
22 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
14 enrolled
CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Dana-Farber Cancer Institute

Phase 2 Recruiting
460 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡